Trevena Announces Reverse Stock Split: A Strategic Move Towards Compliance and Growth
CHESTERBROOK, Pa. Aug.08, 2024 - Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company specializing in the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders, has recently announced its decision to implement a reverse stock split.This strategic move aims to regain compliance with the minimum bid price required for continued listing on the Nasdaq Capital Market, while also positioning the company for long-term growth and success in the biopharmaceutical industry.
With over 21.3 million outstanding shares and a current price of $0.211, Trevena recognizes the need to take proactive measures to comply with the minimum bid price requirement of $1.00.By filing a Certificate of Amendment to its Certificate of Incorporation, Trevena will initiate a reverse stock split at a ratio of 1-for-25.This means that for every 25 shares held, shareholders will receive one share in return, effectively reducing the number of outstanding shares and adjusting the stock price proportionally.
The reverse stock split is scheduled to become effective at 12:01 a.m.ET on Tuesday, August 13, 2024.Following the split, Trevena’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol TRVN.Trading on a split-adjusted basis will commence when the market opens on Tuesday, August 13, 2024.
The primary objective behind this reverse stock split is to regain compliance with the minimum bid price requirement set by the Nasdaq Capital Market.Non-compliance with this requirement can lead to delisting, which would have a detrimental impact on the company’s visibility and investor confidence.By taking this proactive step, Trevena aims to ensure its continued listing on the Nasdaq Capital Market, thereby maintaining access to the financial markets and the potential for increased liquidity.
Executing a reverse stock split not only helps Trevena regain compliance but also signifies the company’s commitment to enhancing shareholder value.Reducing the number of outstanding shares can have a positive psychological impact, as investors perceive the stock price to be higher post-split.This can attract new investors and potentially improve trading volumes, increasing liquidity.
Moreover, the reverse stock split supports Trevena’s long-term growth strategy.It aligns with the company’s focus on developing and commercializing novel medicines for patients with CNS disorders.By regaining compliance with the Nasdaq Capital Market’s requirements, Trevena can access capital more efficiently, enabling further investments in research, development, and clinical trials.
It is important to note that Trevena’s reverse stock split is expected to result in a new CUSIP number for its common stock - 89532E 307.Shareholders will need to update their records and brokerage accounts accordingly to ensure a seamless transition post-split.
In conclusion, Trevena’s decision to implement a reverse stock split demonstrates its commitment to compliance, growth, and enhancing shareholder value.By reducing the number of outstanding shares and adjusting the stock price proportionally, Trevena aims to regain compliance with the minimum bid price requirement set by the Nasdaq Capital Market.This strategic move will not only safeguard Trevena’s continued listing but also provide potential benefits in terms of increased liquidity and improved investor confidence.As the company moves forward, it is poised to leverage this reverse stock split as a catalyst for its ongoing success in the biopharmaceutical industry.
Comments